Kelly Kennedy Buys Shares of GoodRx Holdings, Inc.

On June 16, 2026, Kelly Kennedy, an insider at GoodRx Holdings, Inc. (NasdaqGS: GDRX), purchased 73,434 shares of the company. This transaction was not part of a pre-planned trading program, according to insider filings.

Insider Buying and Selling at GoodRx Holdings, Inc.

Several insiders, including Kelly Kennedy, each bought 73,434 shares of GoodRx Holdings on June 16, 2026. These transactions were not part of a Rule 10b5-1 plan, indicating they were not pre-scheduled. Other insiders involved in similar transactions on the same date include Douglas Joseph Hirsch, Ronald Bruehlman, and others.

Other Institutional Activity in GoodRx Holdings

Francisco Partners Management, LP held steady with 60,078,184 shares, valued at approximately $117.8 million. LSV Asset Management increased its holdings by 2,156,031 shares, reaching a total of 4,981,931 shares worth about $9.8 million. Ameriprise Financial Inc added 1,183,329 shares, bringing its total to 4,455,760 shares valued at $8.7 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both reported new positions, each with over 3 million shares.

GoodRx Holdings, Inc. Stock Down 26.1%

Shares of GoodRx Holdings, Inc. (NasdaqGS: GDRX) traded at $2.73. The company has a market cap of approximately $924.6 million and a P/E ratio of 45.5, with a forward P/E of 7.6. Its beta is 1.615, reflecting higher volatility compared to the market. The stock's 52-week range is between $1.77 and $5.81, with a 50-day moving average of $2.54 and a 200-day moving average of $2.89. GoodRx has a current ratio of 1.47 and a quick ratio of 0.56, indicating its ability to cover short-term liabilities.

Recent Earnings

GoodRx Holdings reported revenue of $787.9 million with a slight decline of 4.4% in revenue growth. The company achieved a net margin of 2.6% and a return on equity of 3.2%. The next earnings report is scheduled for August 5, 2026.

Analysts Set New Price Targets

On May 14, 2026, Citigroup maintained a 'buy' rating for GoodRx with a price target of $4.00. TD Cowen also upheld its 'buy' rating with the same target on May 11, 2026. Wells Fargo continued its 'buy' rating with a target of $3.50 earlier in March 2026. The consensus among 13 analysts is a 'hold' with an average target price of $3.18.

About GoodRx Holdings, Inc.

GoodRx Holdings, Inc. provides a platform that helps consumers compare prescription drug prices and save money. Based in Santa Monica, California, the company offers various healthcare products and services, including subscription programs and telehealth through GoodRx Care. It also serves pharmacy benefit managers by negotiating prices between consumers and pharmacies. Founded in 2011, GoodRx is led by CEO Wendy Barnes and employs 697 people.

Bottom Line

Kelly Kennedy's recent purchase of GoodRx shares highlights ongoing insider interest in the company. With a solid market presence and a suite of healthcare services, GoodRx remains a key player in health information services. However, investors should remember that insider transactions are not necessarily indicative of future performance.